When Diets Don’t Work: Parents Turn to Wegovy for Elementary School Kids

When Diets Don’t Work: Parents Turn to Wegovy for Elementary School Kids

A Young Patient’s Struggle

When Diets Don t Work - In Winder, Georgia, a 7-year-old named Ayden Gatlin-Wright recently received an injection of a weight-loss medication while lying on his living room sofa. His twin brother, Kayden, faces similar challenges, highlighting a growing trend where childhood obesity is prompting medical intervention typically reserved for adults.

For many children, especially those grappling with severe weight issues, traditional methods like dietary changes and physical activity often fail to produce lasting results. This has led to an increasing number of young patients being prescribed drugs such as Wegovy, a GLP-1 receptor agonist, to address their weight concerns.

Doctors are now considering early use of GLP-1 medications to mitigate long-term health risks, including Type 2 diabetes and high blood pressure, which are now appearing in children as young as 4. While these drugs are approved for use in patients aged 12 and older in the U.S., they are being tested in younger children, raising questions about their safety and efficacy.

“We’re seeing kids develop Type 2 diabetes by age 10 or 11,” said Dr. Jessica Reilly, medical director at the Strong4Life pediatric obesity clinic. “They need help so desperately.”

Experts caution that the long-term impact of these medications on growth—particularly bone and brain development—remains uncertain. Without extensive studies, it’s unclear whether the potential benefits outweigh the risks for children still in critical developmental stages. However, some clinicians argue that the severe consequences of untreated obesity justify the use of these drugs.

According to data from 2021 to 2023, approximately 21% of U.S. children and teens aged 2 to 19 are classified as obese, a stark contrast to the 5% prevalence in the 1970s. This rise has sparked debates about the role of early intervention in preventing lifelong health complications.

Dr. Sarah Hampl, a pediatric obesity specialist, acknowledges the potential for positive outcomes but emphasizes the need for more research. “We don’t have enough evidence to safely prescribe under 12 at this point,” she noted, highlighting the uncertainty surrounding long-term effects.

Meanwhile, Dr. Claudia Fox, co-director of the University of Minnesota’s Center for Pediatric Obesity Medicine, stresses the severity of childhood obesity. “Having obesity at 7, especially severe cases, is likely to lead to a reduced quality of life and premature mortality,” she said, underscoring the urgency of treatment for some patients.

While intensive behavioral programs for children are available, they often lack insurance coverage and result in minimal weight loss—typically 1% to 3% in BMI. In contrast, GLP-1 medications have shown more dramatic results, with some patients experiencing up to 20% reductions in body mass index. This discrepancy has fueled discussions about balancing risk and reward in pediatric weight management.

The AAP guideline recommends behavioral therapy for children aged 6 and older, with medication offered to those 12 and up. Yet, the line between treatment and prevention remains blurred as doctors weigh the benefits of early intervention against the unknown long-term effects of these drugs on developing bodies.